Aprepitant boasted a protective effect against olanzapine-induced metabolic syndrome and its subsequent hepatic, renal, and ovarian dysfunction; Role of IGF 1 /p-AKT/FOXO 1 and NFκB/IL-1β/TNF-α signaling pathways in female Wistar albino rats

• Published in: Biochemical pharmacology Vol. 221; p. 116020
• Main Authors: Mohyeldin, Reham H, Abdelzaher, Walaa Yehia, Sharata, Ehab E, Mohamed, Hamza M A, Ahmed, Mohamed Y M, Attia, Josef Zekry, Atta, Medhat, Saleh, Rabeh Khairy, Ghallab, Elshimaa A, Marey, Heba, Elrehany, Mahmoud A, Rofaeil, Remon Roshdy
• Format: Journal Article
• Language: English
• Published: England 01.03.2024
• Subjects: Aprepitant; PCOS; FOXO 1; MS; Hepatorenal injury; IGF 1

Olanzapine-induced metabolic syndrome (MS) is a primary risk factor for insulin resistance, hepatorenal damage, and polycystic ovarian syndrome. The objective of the current study was to assess the protective effects of aprepitant (AP) against MS caused by olanzapine and the associated ovarian, rena...